Los estudios han demostrado que lograr una prdida de peso sostenida del 10 % o ms proporciona beneficios para la salud clnicamente significativos
The trial currently has almost 10,000 patients enrolled and is expected to assess a composite MACE endpoint consisting of cardiovascular (CV) death, non-fatal myocardial infarction, or non-fatal stroke in patients with T2D as is expected to readout in July 2024 (NCT03574597)
Canadians have better access to medications, providing an alternative for those seeking treatment
Clinical trials have shown that GLP-1 probiotics for weight loss, particularly those containing Lactobacillus gasseri, help reduce body weight and waist circumference by modifying gut microbiota
Results should be interpreted alongside clinical history, metabolic markers, and treatment goalsoffering one additional lens through which to evaluate GLP-1 medication fit
Li Y, Wang Q, Liu Y, et al